SOX5 is a member of the high-mobility group superfamily of architectural non-histone proteins involved in gene regulation and maintenance of chromatin structure in a wide variety of developmental processes. Sox5 was identified as a brain tumor locus in a retroviral insertional mutagenesis screen of platelet-derived growth factor B (PDGFB)-induced mouse gliomas. Here we have investigated the role of Sox5 in PDGFB-induced gliomagenesis in mice. We show that Sox5 can suppress PDGFBinduced glioma development predominantly upon Ink4a-loss. In human glioma cell lines and tissues, we found very low levels of SOX5 compared with normal brain. Overexpression of Sox5 in human glioma cells led to a reduction in clone formation and inhibition of proliferation. Combined expression of Sox5 and PDGFB in primary brain cell cultures caused decreased proliferation and an increased number of senescent cells in the Ink4aÀ/À cells only. Protein analyses showed a reduction in the amount and activation of Akt and increased levels of p27 Kip1 upon Sox5 expression that was dominant to PDGFB signaling and specific to Ink4aÀ/À cells. Upon inhibition of p27 Kip1 , the effects of Sox5 on proliferation and senescence could be reversed. Our data suggest a novel pathway, where Sox5 may suppress the oncogenic effects of PDGFB signaling during glioma development by regulating p27
Kip1 in a p19
Arf -dependent manner, leading to acute cellular senescence.
Introduction
Gliomas are the most common primary tumors of the central nervous system (Louis et al., 2007) . The tumors are believed to originate from a glial progenitor cell or an astrocyte based on the expression of various glialspecific mRNAs and proteins in the tumors. Gliomas are diagnosed based on malignancy into four grades (I-IV). Owing to infiltrative growth and a strong tendency of malignant progression of tumor cells, the prognosis is poor even when diagnosed with a low-grade tumor. When diagnosed with the highest-grade glioma, glioblastoma, the average life expectancy is less than a year despite treatment.
In the platelet-derived growth factor B (PDGFB)/ MMLV model candidate genes cooperating with PDGFB in gliomagenesis were identified using a retroviral insertional mutagenesis screen. About 170 integration sites were classified as common integrations and were grouped into 66 Brain tumor loci (Btl) (Johansson et al., 2004) . The Btls included both novel and known genes, some of which had not previously been shown to play a role in brain tumor development (Wolf et al., 2003) . One of the Btls, Sox5, was found by retroviral tagging in three independent tumors, all in forward transcriptional orientation, with two insertions in intron 3 and one in intron 6. The Sox5 locus consists of 15 exons that gives rise to several splice variants (Lefebvre et al., 1998) . Expression of a shorter splice variant of Sox5 has been found in meiotic germ cells of the testis (Connor et al., 1994) and in many different cell types of the brain, such as ventricular zone progenitors, radial glia and oligodendrocyte precursors (Stolt et al., 2006) . Expression of a longer splice variant of Sox5 has been detected in chondrogenic cells and developing brain and neural tube (Lefebvre et al., 1998) .
The SOX family of high-mobility group domain proteins has an important role as chromatin modulators and transcription factors in diverse processes of embryonic development and cell-type specification (Wegner, 1999; Akiyama et al., 2002; Wegner and Stolt, 2005) . There are 20 Sox genes identified, and these can be divided into different subgroups, A-H, based on the sequence identity of the high-mobility group domain. Gliogenesis is dependent on SoxD (Sox5, Sox6, Sox13) and SoxE (Sox8, Sox9, Sox10) genes (Stolt et al., 2006) . In the mouse spinal cord, it has been suggested that oligodendrocyte development is regulated by Sox5 and Sox6 proteins modulating the function of Sox9 and Sox10 proteins (Stolt et al., 2006) . SoxE proteins are necessary for oligodendrocyte specification and differentiation and it is believed that SoxD proteins counteract their effect and regulate the timing of oligodendrocyte development.
Expression and amplification of many SOX genes have been implicated in human cancer (Dong et al., 2004) . SOX5, DAD-R and EKI1 belong to a 12p amplicon found in human testicular seminomas (Zafarana et al., 2002) . The amplicon can be related to invasive growth and reduced apoptosis in the tumors. However, most data implicate DAD-R to be the candidate gene responsible for the pathological effects resulting from the 12p gain. Thus, so far the only causative evidence of an oncogenic effect by a SOX gene has been shown for SOX3, where ectopic expression could induce oncogenic transformation of chicken fibroblasts in vitro (Xia et al., 2000) . There are contradictory reports regarding the expression of SOX5 glioma. In one study, SOX5 protein expression was found in gliomas of all grades at levels above that of normal adult brain (Ueda et al., 2007) . Furthermore, glioblastoma patients carrying immunoglobulin G antibodies against SOX5 exhibited significantly better survival than those without SOX5 antibodies (Ueda et al., 2007) . However, in a study of SOX5, SOX9 and SOX10, mRNA expression in glioma tumors of all grades were found to express lower or equal mRNA levels than normal adult brain (Schlierf et al., 2007) . Supporting this data, a recent SAGE analysis showed no or very low levels of SOX5 expression in glioblastomas compared with normal brain (Parsons et al., 2008) .
The somatic cell gene transfer model replicationcompetent avian leukemia virus splice acceptor/ avian leukemia virus receptor (RCAS/tv-a) has been frequently used to study oncogenic mechanisms of gliomagenesis (Holland et al., 2000; Dai et al., 2001; Uhrbom et al., 2002 Uhrbom et al., , 2005 Tchougounova et al., 2007) . Infection with RCAS retroviruses carrying specific genetic mutations can be directed to specific brain cell populations using transgenic mice expressing tv-a from cell type-specific promoters. In Ntv-a mice, the nestin promoter supports gene transfer by RCAS to neural/ glial progenitor cells, and in Gtv-a mice the glial fibrillary acidic protein promoter directs transfer to astrocytes in the newborn mouse brain.
Here we have investigated the role of Sox5 in PDGFB-induced glioma development using the RCAS/tv-a model. Homozygous deletion of CDKN2a, encoding p14 ARF (p19 Arf in the mouse) and p16
INK4a
, is one of the most common mutations found in human glioblastoma (Jen et al., 1994; Parsons et al., 2008) . As there are differences in the abilities of p19
Arf and p16
Ink4a
to suppress gliomagenesis in vivo (Uhrbom et al., 2005; Tchougounova et al., 2007) , we decided to investigate how separate and combined loss of Ink4a and Arf would cooperate with Sox5 expression. We found that Sox5 could suppress PDGFB-induced glioma development in vivo predominantly in Ink4a-deficient mice, and we provide data suggesting the mechanism to be through the regulation of p27 Kip1 and Akt causing an immediate cellular senescence.
Results
The mode of the retroviral integrations targeting Sox5 in the PDGFB/MMLV tumors (Johansson et al., 2004) suggested that they could have caused an overexpression of a short splice variant of Sox5 and/or disruption of a long splice variant of Sox5. To investigate if Sox5 could be oncogenic, Ntv-a and Gtv-a wild-type (wt), Ink4aÀ/À, ArfÀ/À, and Ink4a-ArfÀ/À mice were injected with RCAS-Sox5 (Table 1) . No tumors To study the effect of Sox5 expression on PDGFBinduced gliomagenesis RCAS-Sox5 was injected together with RCAS-PDGFB in Ntv-a and Gtv-a wt, Ink4a-and Arf-deficient mice ( Table 1) . As control for these injections RCAS-X (empty RCAS virus) þ RCAS-PDGFB were injected. Comparisons of tumor incidences between Sox5 þ PDGFB and X þ PDGFB for the different genetic backgrounds (Table 2) suggested that Sox5 could suppress PDGFB-induced glioma development in Gtv-a wt mice and in both Ntv-a and Gtv-a Ink4a-deficient mice. There were significant decreases in tumor incidences for all these groups when comparing Sox5 þ PDGFB and X þ PDGFB (Table 2) . Thus, Sox5 could not cause glioma formation by itself or enhance PDGFB-induced gliomagenesis, but rather caused tumor suppression particularly in Ink4a-deficient mice.
The SOX5 protein expression was investigated in human glioma cells and tissues. Of 11 glioma cell lines investigated, all but one were negative for SOX5 (Figures 1a and b) . The analysis of human brain tissues showed that SOX5 was expressed at low levels in normal cortex where expression was confined to neurons ( Figure 1c ). Four gliomas were entirely negative for SOX5 (Figure 1d ), four gliomas showed similar expression level as normal cortex where expression was mostly found in neurons (Figure 1e ), and the remaining three gliomas showed SOX5 expression in both neurons and glial cells within the tumor (Figure 1f) .
To investigate the ability of Sox5 to suppress tumorigenesis of human glioma cells, we performed a clone formation assay ( Figure 2a ). Cells were transfected with Sox5, PDGFB or eGFP and the number of stably transfected clones were counted 15 days later. Expression of Sox5 and eGFP were analyzed with immunofluorescence staining 3 days after transfection (data not shown) and at termination of the experiment (Figures 2b and c). Data showed that Sox5 could significantly inhibit clone formation in all glioma cell lines investigated with an average of 27.5% compared with controltransfected cells. Conversely, PDGFB enhanced clone formation with 29.5%. The ability of Sox5 to suppress clone formation in human glioma cell lines supported the tumor suppressing effect by Sox5 found in vivo.
Furthermore, in the eGFP-transfected cells more than 80% of the clones were entirely eGFP positive (Figure 2b ), whereas in the Sox5-transfected cells only about 50% of the clones expressed Sox5, and the majority of these clones were only semi-positive for Sox5 (o50% positive cells per clone) (Figure 2c ).
To further examine the function of Sox5 in gliomagenesis, we established Sox5-inducible U-251MG glioma cells using the RheoSwitch system. Two Sox5-inducible clones were established and they showed a robust induction of Sox5 after 1 day that remained high after 7 days of induction (Figures 3a and b) . The effect of induced Sox5 on cell proliferation was investigated and we found a small but consistent effect on cell numbers (Figure 3c ). The reduction in the two Sox5-inducible clones were on average 13 and 16%, respectively, compared with control cells. Similar outcome in two independent clones strongly support that the effect is due to the induced expression of Sox5 and not the result of clonal variation.
To investigate the molecular mechanism by which Sox5 caused suppression of PDGFB-induced gliomagenesis, we performed in vitro tissue culture experiments. As we found the most significant effects by Sox5 on tumor initiation in Gtv-a mice and a striking effect when comparing Ink4a-and Arf-deficient mice from both Ntv-a and Gtv-a lines, we used primary cells from neonatal Gtv-a Ink4aÀ/À and ArfÀ/À brains to try to identify Sox5-induced differential effects dominant to PDGFB expression in Ink4aÀ/À cells. The cells were infected with RCAS-PDGFB-HA, RCAS-V5-Sox5 and RCAS-eGFP. Expression of PDGFB and Sox5 was confirmed with immunofluorescence staining for HA and V5, respectively (Figures 4a and b) . The significant effect of Sox5 on tumor suppression in vivo in both Ntva and Gtv-a Ink4a-deficient mice suggested that Sox5 could compensate for the loss of p16
Ink4a in PDGFBinduced oncogenesis. This led us to hypothesize that Sox5 might interact, directly or indirectly, with some protein of the Rb pathway downstream of p16 Ink4a . Primary candidate proteins would be Cyclin D1 and Cdk4, which in complex are positive regulators of the G1 to S transition of the cell cycle by inhibiting Rb function (Weinberg, 1995) . The expression of Cyclin D1 and Cdk4 were investigated (Figure 4c ). In Ink4aÀ/À cells, the expression of both Cyclin D1 and Cdk4 were decreased in Sox5-infected cells compared with control cells (eGFP infected) but the effect was completely counteracted by simultaneous expression of PDGFB. In ArfÀ/À cells, the Cyclin D1 expression was equal in Sox5-and PDGFB-infected cells, whereas Cdk4 was decreased in both Sox5-and PDGFB-infected cells compared with control cells (Figure 4c) . However, the Sox5 expression also had a slight effect on reducing the level of p16
Ink4a in the ArfÀ/À cells, an effect that would counteract the reduction in Cdk4 protein in these cells.
We analysed the effect of Sox5 on the p19 Arf signaling pathway, as an alternative hypothesis could be that Sox5 would enhance the effect of the p19
Arf signaling in Ink4aÀ/À cells specifically. We found that Sox5 could Figure 4c ). The effect of Sox5 on p53 expression was equal to that in control cells in both Ink4aÀ/À and ArfÀ/À cells (Figure 4c ), suggesting no . We found no correlation between p53 and p21 Cip1 levels and no specific induction of p21 Cip1 in Sox5 þ PDGFB-infected Ink4aÀ/À cells (Figure 4c) . Cellular senescence is a largely irreversible growth arrest, where the cells are arrested in the G0/G1 phase of the cell cycle and do not enter S phase in response to growth factors (Sherwood et al., 1988) . Senescent cells undergo distinctive changes in cell morphology becoming enlarged and flattened (Goldstein, 1990) , and can be detected with an assay detecting SA-b-gal activity (Dimri et al., 1995) . SA-b-gal corresponds to lysosomal b-galactosidase that accumulates to very high levels in senescent cells, which makes it possible to detect its activity even at sub-optimal pH (Lee et al., 2006) . When infecting the primary Gtv-a Ink4aÀ/À and Gtv-a ArfÀ/À cells with Sox5 and/or PDGFB, we found that there was an increase in big, flat cells, reminiscent of senescent cells in Sox5-infected Ink4aÀ/À and ArfÀ/À cells and in Sox5 þ PDGFB-infected Ink4aÀ/À cells (data not shown). We performed SA-b-gal staining of these cells (Figure 5a ) and found that there were an increased number of SA-b-gal-positive cells in Ink4aÀ/À cells infected with Sox5 þ PDGFB or Sox5 alone (Figure 5b ).
In ArfÀ/À cells, there was an increased number of SA-b-gal-stained cells in Sox5-infected cells only. We also performed immunofluorescence stainings for V5 (Sox5 expression) on SA-b-gal-stained cells infected with Sox5 þ PDGFB. In Ink4aÀ/À cells infected with Sox5 þ PDGFB, over 90% of the cells showed colocalization of SA-b-gal and V5 (Figure 5c ), whereas in the ArfÀ/À cells about 50% of V5-positive cells were SA-b-gal positive (Figure 5d) .
To study the proliferation status of Sox5 þ PDGFBinfected Ink4aÀ/À and ArfÀ/À cells, expression of Ki-67, a marker of cell proliferation, was analyzed with triple immunofluorescence stainings (Figures 5e and f) . In Ink4aÀ/À cells, HA (PDGFB expression) and V5 (Sox5 expression) double-positive cells were completely negative for Ki-67 (Figure 5e ), whereas in ArfÀ/À cells, about 20% of the HA þ V5 double-positive cells also expressed Ki-67 (Figure 5f ).
Thus, expression of Sox5 could induce inhibition of cell proliferation and acute cellular senescence in primary Gtv-a cells lacking either p16
Ink4a or p19 Arf . In addition, this ability seemed to be dominant to PDGFB transformation in the Ink4aÀ/À cells only. This result could explain the outcome of the in vivo study where Sox5 could suppress PDGFB-induced tumor initiation in Ink4aÀ/À mice but not in ArfÀ/À mice. 
The p16

Ink4a
, p19
Arf and p27 Kip1 cell cycle inhibitors are regarded as central mediators in the regulation of cellular senescence (Bringold and Serrano, 2000) . As we had not found any effects in the p16
Ink4a and p19
Arf pathways that could explain the specific Sox5 þ PDGFB-induced senescent response in Ink4aÀ/À cells, we investigated the levels of p27 Kip1 and related proteins in Sox5 and/or PDGFB-infected primary Ink4aÀ/À and ArfÀ/À cells. p27
Kip1 is a negative regulator of the G1 to S-phase transition of the cell cycle and is functionally inactivated in many human cancers (Chu et al., 2008) . The phosphatase and tensin homolog (PTEN) tumor suppressor antagonizes the phosphatidylinositol 3-kinase (PI3K) actions and can regulate protein stability of p27
Kip1 (Li and Sun, 1998; Sun et al., 1999 ) through repression of SKP2, a component of the ubiquitin E3 ligase SCF SKP2 complex (Mamillapalli et al., 2001) . In addition to regulating the protein stability of p27 Kip1 , the PTEN/PI3 K pathway can also regulate cellular localization of p27 Kip1 . Activated Akt has been shown to phosphorylate p27
Kip1 at T157, leading to cytoplasmic localization of p27 Kip1 , which has been correlated with tumor dedifferentiation and poor prognosis (Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) . When analyzing p27
Kip1 protein levels, we found that p27 Kip1 was clearly upregulated in the Sox5-infected Ink4aÀ/À cells compared with control and PDGFB-infected cells and that it remained high in the Sox5 þ PDGFB-infected cells (Figure 4d ). There was a slight increase of p27
Kip1 also in Sox5-infected ArfÀ/À cells compared with control cells, but that effect was abolished with the addition of PDGFB (Figure 4d ). The total and activated levels of Akt were decreased specifically in the Sox5-stimulated Ink4aÀ/À cells compared with control and PDGFB cells and remained lower in the Sox5 þ PDGFB-infected cells compared with PDGFB alone (Figure 4d ). In the Arf-deficient cells, the total levels of Akt were greatly increased compared with the Ink4aÀ/À cells (Figure 4d ). This has been noted earlier and could be due to a compensatory mechanism required to overcome the increased levels of p16
Ink4a in these cells (Tchougounova et al., 2007) . The effect by Sox5 on Akt activation in the ArfÀ/À cells was clearly different than that in the Ink4aÀ/À cells causing increased activation of Akt (Figure 4d ). Thus, in the Ink4aÀ/À cells, Sox5 expression led to a specific increase in p27
Kip1 and a reduction in total and activated Akt protein levels that was not observed in the ArfÀ/À cells. Furthermore, the levels of p27 Kip1 could not be directly correlated with the levels of Pten in the Ink4aÀ/À cells (Figure 6c ), supporting the hypothesis that p27 Kip1 could be one mediator of Sox5 signaling in Ink4a-deficient cells.
Discussion
Our results suggest that the specific tumor suppressive effect by Sox5 in Ink4a-deficient mice could be due to activation of p27 Kip1 , leading to acute cellular senescence, thereby protecting them from PDGFB-induced glioma development. The fact that inhibition of p27 Kip1 in the Ink4aÀ/À primary cells did not cause a complete reversal of the Sox5-induced effect on cell proliferation and senescence could be due to an incomplete inhibition of p27 Kip1 , or more likely, Sox5 may control many as yet unknown cellular pathways other than p27 Kip1 . In the in vivo studies, the longer version of the PDGFB cDNA (RCAS-PDGFB-eGFP) was used. This virus generates 4-to 15-fold lower levels of PDGFB in the target cells than RCAS-PDGFB-HA (Shih et al., 2004) used in the tissue culture experiments. Earlier studies have shown that higher levels of PDGFB caused increased incidence and malignancy of tumors (Shih et al., 2004) . It may be so that the level of PDGFB could affect the ability of Sox5 to suppress gliomagenesis; however, the in vitro data suggest that Sox5 can suppress also high PDGFB signaling.
Preceding this work, there had been ambiguous reports on the expression of SOX5 in human glioma. One study, comprising six glioma tissues and three glioma cell lines, argued for overexpression of SOX5 in glioma (Ueda et al., 2007) . However, two other investigations showed, independently of each other, that there in general was low or no expression of SOX5 in glioma. In these studies, the SOX5 mRNA expression was analysed in a large set of patient samples (16 and 60) (Schlierf et al., 2007; Parsons et al., 2008) . In accordance with these studies, our data showed that SOX5 overall was expressed at very low levels in various human glioma cell lines and tissues. We also showed that SOX5 expression could inhibit clone formation to a similar extent in all glioma cell lines investigated. We established SOX5-inducible cells and found that proliferation of the human glioma cell line U-251MG was decreased upon expression of SOX5. Taken together, it supports a suppressing role of SOX5 in glioma development.
In a recent study of nasopharyngeal carcinoma development, SOX5 was proposed to act as an oncoprotein. The upregulation of SOX5 was suggested to cause a transcriptional repression of the secreted glycoprotein SPARC, which in turn would lead to progression of the tumors (Huang et al., 2008) . However, in gliomas of all grades, SPARC has been found to be highly expressed in tumor cells, angiogenic endothelial cells and tumor-adjacent reactive astrocytes (Rempel et al., 1998) promoting invasion of tumor cells (Schultz et al., 2002) and supporting a different role of SOX5 in glioma development. 
Sox5 suppression of PDGF-induced glioma development E Tchougounova et al
The mechanism by which Sox5 suppressed PDGFinduced glioma development is suggested to be through induction of acute cellular senescence. We discovered that Sox5 could induce a significant increase in SA-b-gal-stained cells in both Ink4aÀ/À and ArfÀ/À primary glial cells. However, the effect of Sox5 on cellular senescence was dominant to simultaneous PDGFB infection in Ink4aÀ/À cells only. There was a small but consistent effect by Sox5 on human glioma cell proliferation and a nonsignificant increase in cellular senescence (data not shown) in the Sox5-inducible glioma cells. This discrepancy in response to Sox5 between the primary glial cells and human glioma cells is reasonable, as the senescence response to Sox5 expression dominant to oncogenic stimulation in the primary cells was dependent on the presence of p19
Arf . In the majority of human glioma cell lines (Kamb et al., 1994; Nobori et al., 1994) , including U-251MG, the CDKN2a locus is homozygously deleted (data not shown), thus the cells do not express p14
ARF . In addition, human glioma cells are likely to hold numerous other mutations that may interfer with the SOX5-induced senescence pathway. Moreover, the effect of Sox5 on PDGFBinduced gliomagenesis appeared to act on tumor initiation, as in most Sox5 þ PDGFB-injected Ink4aÀ/À mice there were no signs of tumor lesions. Thus, it may be reasonable to expect the effect in vitro would be greater in normal, primary glial cells than in glioma cell lines established from highly malignant tumors. There was no significant difference in malignancy between tumors from Sox5 þ PDGFB and X þ PDGFB in Ntv-a wt, Ntv-a ArfÀ/À and Gtv-a ArfÀ/À mice, where the tumor incidence rates were similar between the two groups, suggesting a limited role of Sox5 in suppressing tumor progression.
In the mouse, Sox5 is expressed in oligodendrocyte progenitor cells at a specific stage during oligodendrocyte differentiation. Such an expression may confer resistance to transformation by tumor-initiating stimuli. The fact that PDGFB/MMLV-induced mouse gliomas expressed no or low levels of Sox5, as did most human gliomas investigated, support this view. Although the mechanism of Sox5-mediated tumor suppression has not yet been fully clarified, the observation that the proportion of cells with a senescent phenotype was significantly increased upon combined Sox5 and PDGFB expression is highly interesting, and suggests a novel pathway activating an acute cellular senescence response that is dependent on p19
Arf but not p16
Ink4a . Additional pathways regulated by Sox5 and mechanisms to reactivate these should be further explored in our efforts to find better treatment for malignant glioma.
Materials and methods
In vivo virus infection and tumor surveillance Ntv-a and Gtv-a mouse lines (Tchougounova et al., 2007) were infected with DF-1 chicken fibroblasts producing RCAS-PDGF-ires-EGFP, RCAS-V5-Sox5 or RCAS-X (empty RCAS virus) alone or in combination, monitored and analysed for presence of tumors as described (Uhrbom et al., 2005) . Experiments were performed in accordance with the local animal ethics committee.
Tissue culture and proliferation assay Primary cell cultures were prepared from neonatal Gtv-a Ink4aÀ/À or Gtv-a ArfÀ/À mice as described (Uhrbom et al., 2005) , expanded for two passages and stored as frozen aliquots. Cells were infected with RCAS-PDGFB-HA, RCAS-V5-Sox5 or RCAS-EGFP (control virus) daily for 5 days. Human glioma cell lines U-178MG, U-251MG, U-343MG, U-343MGa Cl2:6, U-1242MG, the glioma cell cultures 4, 8,18, 21, 34, 35 (Hagerstrand et al., 2006) , and normal human foreskin fibroblasts 1064SK and AG1523 were used.
For proliferation analysis, 10 4 cells per 35 mm dish were seeded and grown in the presence of dimethylsulfoxide or RSL ligand. The cell number was determined using a Coulter counter (Coulter Electronics, Herpendon, UK).
Tissue microarray and immunohistochemical staining
Immunohistochemical staining for SOX5 (Abcam, Cambridge, UK) of tissue microarrays including normal and cancer tissue was performed in collabration with the Swedish Human Protemome Resource Project (Uhlen and Ponten, 2005) . Two samples from human brain cortex and 11 gliomas were representative and used for annotation of SOX5.
Western blot analyses
Protein extracts and western blots were performed as described (Uhrbom et al., 2005) . Membranes were blotted with primary antibodies against phospho-Akt (Thr308) (Cell Signaling, Danvers, MA, USA), Akt (Cell Signaling), Pten (26H9) (Cell signaling), p27
Kip1 (K25020) (BD Transduction Laboratories, San Diego, CA, USA), p21 WAF1/Cip1 (M-19) (Santa Cruz; Santa Cruz, CA, USA), p53 (DO-1) (Santa Cruz), p16
Ink4a (M-156) (Santa Cruz), p19 ARF (ab80) (Abcam), Cyclin D1 (H-295) (Santa Cruz Biotechnology), HA-probe (Y-11) (Santa Cruz), V5-probe (Serotec, Oxford, UK), (Santa Cruz). Ponceau S (Sigma, St Louis, MO, USA) red staining was used to confirm equal protein loading and protein transfer to the membrane.
Clone formation assay
On day 1, 7 Â 10 5 cells per dish were seeded. Day 2, cells were transfected with pcDNA-eGFP, pcDNA-V5-Sox5 or pcDNA-PDGFB by using Fugene (Roche, Mannheim, Germany). Day 5, G418 (Calbiochem, Darmstadt, Germany) was added at 0.8 mg/ ml. Day 15, cells were fixed in methanol, stained with Giemsa (Merck, Darmstadt, Germany) and clones were counted.
Generation of Sox5-inducible glioma cells
The RheoSwitch Mammalian Inducible Expression System (New England Biolabs, Hertfordshire, UK) was used. V5-Sox5 was inserted into the pNEBR-X1 Hygro vector. U-251MG cells were transfected with the pNEBR-R1 plasmid and selected in media containing G418. G418-resistant clones were screened for RheoSwitch function using transient transfection of pNEBR-X1Gluc. The clone with the highest RSL1 induction ratio was transfected with the pNEBR-X1-V5-Sox5 Hygro vector. Cells were selected in hygromycin þ G418 containing media and clones were screened for induction of Sox5. The RSL1 ligand was dissolved in dimethylsulfoxide at 50 nM.
Senescence-associated b-galactosidase staining Primary brain cells were infected for 5 days with RCAS-PDGFB-HA, RCAS-V5-Sox5 or their combination. Late Sox5 suppression of PDGF-induced glioma development E Tchougounova et al passage AG 1523 and early passage SK 1064 were used as positive and negative controls, respectively. SA-b-gal staining was performed as described (Dimri et al., 1995) .
Immunocytochemical analyses
Sox5 was induced with RSL ligand for 4 days. Cells were fixed in 4% paraformaldehyde, washed in phosphate-buffered saline, treated with 0.2% Triton X-100 and blocked for 1 h in 1% bovine serum albumin þ 5% fetal bovine serum. Primary antibodies against mouse Sox5 (C-20, Santa Cruz), human SOX5 (Abcam), V5 (Abcam), eGFP (Abcam), Sox6 (Santa Cruz), Ki-67 (Dako) and HA (Santa Cruz) were used. Secondary antibodies used were chicken anti-goat Alexa 488 (Invitrogen, Eugene, OR, USA), donkey anti-mouse RRX (Jackson, Suffolk, UK), goat anti-rat Alexa 488 (Invitrogen) and donkey anti-rabbit Alexa 647 (Invitrogen).
RNA interference of p27 Kip1
Day 1, 5 Â 10 4 cells per well were seeded in six-well plates. Day 2, cells were transfected with control siRNA or siRNA against p27
Kip1 (Dharmacon, Lafayette, CO, USA). After 24 h transfection, media was replaced by viral supernatants containing RCAS-PDGFB-HA þ RCAS-V5-Sox5 or RCAS-PDGFB-HA þ RCAS-X. Infection was repeated every day for 5 days after which the number of cells was counted, SA-b-gal staining was performed or proteins were extracted for western blot analysis.
